<DOC>
	<DOCNO>NCT02618759</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic efficacy safety DSXS compare Placebo ( vehicle ) patient mild moderate plaque psoriasis .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety DSXS Patients With Mild Moderate Plaque Psoriasis</brief_title>
	<detailed_description>To evaluate therapeutic efficacy safety dsxs topical spray , 0.15 % ( Taro Pharmaceuticals , U.S.A. , Inc. ) compare Placebo ( vehicle ) spray ( Taro Pharmaceuticals , U.S.A. , Inc. ) patient mild moderate plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>male nonpregnant female , 12 year age old , confirm diagnosis mild moderate plaque psoriasis patient &lt; 12 year old .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>